Nitisinone baked tablet    (DrugBank: Nitisinone)

2 diseases
IDDisease name (Link within this page)Number of trials
164Oculocutaneous albinism0
241Hypertyrosinemia type I1

164. Oculocutaneous albinism    [ 15 clinical trials,   57 drugs,   (DrugBank: 34 drugs),   34 drug target genes,   136 drug target pathways]
Searched query = "Oculocutaneous albinism", "Hermansky-Pudlak syndrome", "Chediak-Higashi syndrome", "Griscelli syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: . Trials are sorted by Date_enrollment from most recent to oldest in the table.
0 / 15 trial found

241. Hypertyrosinemia type I    [ 14 clinical trials,   7 drugs,   (DrugBank: 1 drug),   1 drug target gene,   5 drug target pathways]
Searched query = "Hypertyrosinemia type I", "Tyrosinemia type I", "Tyrosinemia I", "Hereditary tyrosinemia, Type I", "Fumarylacetoacetate hydrolase deficiency", "FAH deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 14 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02750345
(ClinicalTrials.gov)
March 201621/4/2016Bioequivalence Study of Two Oral Nitisinone Formulations to Treat Hereditary Tyrosinemia (HT-1)A Three-Period Crossover Study to Determine the Bioequivalence of Two Oral Formulations Containing Nitisinone 10 mg Compared to Reference Formulation Orfadin In Healthy Subjects Under Fasting ConditionsHereditary Tyrosinemia, Type IDrug: Nitisinone;Drug: Nitisinone Baked Tablet;Drug: OrfadinCycle Pharmaceuticals Ltd.ParexelCompleted18 Years55 YearsAll24Phase 1South Africa